PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ:ARWR) announced today that its majority-owned subsidiary, Insert Therapeutics, Inc. has entered into a collaboration agreement with R&D-Biopharmaceuticals GmbH to develop and commercialize conjugates of the potent anti-cancer compound tubulysin with Insert’s proprietary drug delivery system, CyclosertTM. The agreement provides a research license and an option for an exclusive license to develop and commercialize tubulysin-polymer conjugates.
